Choosing the right antidepressant could soon become a science rather than a guessing game. A new study led by researchers at the University of California, Irvine and McLean Hospital found that using biological and behavioral markers to guide treatment selection boosted patient response rates by nearly 67%.
The Research
Published in Nature Mental Health on July 6, 2026, the study tested whether combining fMRI brain connectivity, cognitive reward sensitivity tests, and clinical profiles could predict how patients would respond to two common antidepressants: sertraline (a serotonin booster) and bupropion (which targets norepinephrine and dopamine).
The team, led by Dr. Diego A. Pizzagalli, analyzed data from the national EMBARC study and built predictive algorithms. In a prospective test with fewer than 50 patients, those with favorable biomarker signatures achieved a 71.4% response rate, compared to just 42.8% for those without any positive markers — a roughly 67% improvement.
Why It Matters
Currently, only 30% to 50% of people with major depression respond to their first antidepressant. The trial-and-error process can take months, during which symptoms worsen. This study shows that depression isn't a single disease; it's driven by different biological pathways in different people. Tools like brain scans and cognitive tests could eventually help doctors bypass standard pills and fast-track patients to treatments like ketamine or brain stimulation.
What You Can Do
While this biomarker tool isn't ready for clinics yet, you can learn more about your own brain by exploring cognitive tests that measure reward sensitivity, attention, and memory. Understanding your cognitive profile may help you and your doctor make better decisions down the line.
Source: Neuroscience News
Curious about your own brain? Take our free adaptive IQ test or try 306 brain training levels.
